Ghareeb, M., Arafa, O., Sabry, A., Emam, S., Helal, H. (2024). Safety and efficacy of Clopidogrel versus Ticagrelor in treating Non-STEMI elderly patients. Benha Journal of Applied Sciences, 9(1), 147-150. doi: 10.21608/bjas.2024.261902.1310
Magdy Abdallah Ghareeb; Osama Sanad Arafa; Alshimaa Mohammed Sabry; Safaa Salah Emam; Hatem Ibrahim Helal. "Safety and efficacy of Clopidogrel versus Ticagrelor in treating Non-STEMI elderly patients". Benha Journal of Applied Sciences, 9, 1, 2024, 147-150. doi: 10.21608/bjas.2024.261902.1310
Ghareeb, M., Arafa, O., Sabry, A., Emam, S., Helal, H. (2024). 'Safety and efficacy of Clopidogrel versus Ticagrelor in treating Non-STEMI elderly patients', Benha Journal of Applied Sciences, 9(1), pp. 147-150. doi: 10.21608/bjas.2024.261902.1310
Ghareeb, M., Arafa, O., Sabry, A., Emam, S., Helal, H. Safety and efficacy of Clopidogrel versus Ticagrelor in treating Non-STEMI elderly patients. Benha Journal of Applied Sciences, 2024; 9(1): 147-150. doi: 10.21608/bjas.2024.261902.1310
Safety and efficacy of Clopidogrel versus Ticagrelor in treating Non-STEMI elderly patients
1Cardiology Departement, Nasr City Health insurance hospital , Cairo , Egypt.
2Professor of Cardiology Faculty of Medicine-Benha University
3Assistant Professor of Cardiology Faculty of Medicine- Benha University
4Lecturer of Cardiology Faculty of Medicine- Benha University
5Consultant of Cardiology Health Insurance Hospitals
Abstract
Background: Acute coronary syndrome describes a wide range of clinical conditions that are caused by acute myocardial ischemia. A mismatch between myocardial oxygen demand and supply constitutes the fundamental pathology of ACS. An independent risk factor for major adverse events following acute coronary events, age is furthermore, being a significant risk factor for atherosclerotic cardiovascular disease. In order to prevent recurrent thrombotic events in patients with dual antiplatelet therapy non-ST-elevation acute coronary syndrome, comprising a P2Y12 inhibitor and aspirin is critically important. For their demonstrated anti-inflammatory effects in addition to their antithrombotic properties, antiplatelet medications have been utilised to improve clinical outcomes in patients with atherosclerotic cardiovascular diseases. Methodology: The study. The study included 200 elderly patients presenting with NSTEMI. They were categorized into two groups: group 1: 100 NSTEMI patients received clopidogre, and group 2: 100 NSTEMI patients received ticagrelor. Results: Patients who received clopidogrel demonstrated significantly lower minor bleeding (P = 0.011) and overall bleeding (P < 0.001). Additionally, major bleeding was reduced in participants who received clopidogrel than in patients who received ticagrelor but without statistical significance (P = 0.123). Insignificant differences were reported regarding stent thrombosis, stroke, myocardial infarction, CV death, urgent revascularization and transient ischemic attacks. Conclusion: As an alternative to ticagrelor, clopidogrel is beneficial for elderly patients. Without increasing ischemic risk, clopidogrel is associated with a significantly reduced risk of major and minor bleeding.